Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Spero Therapeutics (SPRO) Cash from Investing Activities (2016 - 2022)

Spero Therapeutics (SPRO) has disclosed Cash from Investing Activities for 6 consecutive years, with -$129000.0 as the latest value for Q3 2022.

  • For the quarter ending Q3 2022, Cash from Investing Activities fell 100.76% year-over-year to -$129000.0, compared with a TTM value of -$129000.0 through Jun 2023, down 100.47%, and an annual FY2022 reading of $33.8 million, up 340.65% over the prior year.
  • Cash from Investing Activities was -$129000.0 for Q3 2022 at Spero Therapeutics, down from $50.0 million in the prior quarter.
  • Across five years, Cash from Investing Activities topped out at $50.0 million in Q2 2022 and bottomed at -$72.6 million in Q3 2018.
  • Average Cash from Investing Activities over 5 years is -$88263.2, with a median of $3.9 million recorded in 2020.
  • The sharpest move saw Cash from Investing Activities skyrocketed 396.9% in 2019, then plummeted 869.5% in 2020.
  • Year by year, Cash from Investing Activities stood at $7.3 million in 2018, then tumbled by 156.25% to -$4.1 million in 2019, then tumbled by 869.5% to -$39.7 million in 2020, then soared by 41.43% to -$23.3 million in 2021, then soared by 99.45% to -$129000.0 in 2022.
  • Business Quant data shows Cash from Investing Activities for SPRO at -$129000.0 in Q3 2022, $50.0 million in Q2 2022, and -$16.1 million in Q1 2022.